# Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States

> **NCT00997386** · PHASE2 · COMPLETED · sponsor: **University of Arizona** · enrollment: 16 (actual)

## Conditions studied

- Hematologic Neoplasms
- Multiple Myeloma
- Anemia, Aplastic
- Hemoglobinuria, Paroxysmal
- Myelofibrosis

## Interventions

- **DRUG:** busulfan, and melphalan, and alemtuzumab

## Key facts

- **NCT ID:** NCT00997386
- **Lead sponsor:** University of Arizona
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-09
- **Primary completion:** 2014-04
- **Final completion:** 2016-01
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2019-09-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00997386

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00997386, "Reduced Intensity Allogeneic PBSCT to Treat Hematologic Malignancies and Hematopoietic Failure States". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00997386. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*